Switching to Vortioxetine in Patients with Poorly Tolerated Antidepressant-Related Sexual Dysfunction in Clinical Practice: A 3-Month Prospective Real-Life Study

Switching to Vortioxetine in Patients with Poorly Tolerated Antidepressant-Related Sexual Dysfunction in Clinical Practice: A 3-Month Prospective Real-Life Study

Treatment-emergent sexual dysfunction (TESD) is one of the most frequent and persistent adverse effects of antidepressant medication. Sexual dysfunction (SD) secondary to SSRIs occurs in >60% of sexually active patients and >80% of healthy volunteers, with this causing treatment discontinuatio...

Full description

Bibliographic Details
Main Authors:	Angel L. Montejo, Froilán Sánchez-Sánchez, Rubén De Alarcón, Juan Matías, Benjamin Cortés, Claudia Matos, Tomás Martín-Pinto, Peñitas Ríos, Nerea González-García, José María Acosta
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Journal of Clinical Medicine
Subjects:	sexual dysfunction antidepressant vortioxetine depression sexuality
Online Access:	https://www.mdpi.com/2077-0383/13/2/546

Similar Items

Hypomanic switch during vortioxetine treatment: a case report
by: Efruz Pirdoğan Aydın, et al.
Published: (2019-01-01)

Review of a New Multimodal Antidepressant Vortioxetine
by: Oppa M, et al.
Published: (2016-08-01)

The use of vortioxetine for depression in patients with Parkinson's disease in the early and advanced stages of the disease
by: I. V. Miliukhina
Published: (2020-10-01)

Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents
by: Jessica A. Waller, et al.
Published: (2017-08-01)

Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy—Case Series
by: Marcin Siwek, et al.
Published: (2022-03-01)

The antidepressant drugs vortioxetine and duloxetine differentially and sex-dependently affect animal well-being, cognitive performance, cardiac redox status and histology in a model of osteoarthritis
by: Katarina Nastić, et al.
Published: (2023-10-01)

Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
by: Marcin Siwek, et al.
Published: (2021-05-01)

Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan
by: Inoue T, et al.
Published: (2021-12-01)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
by: Bing Cao, et al.
Published: (2019-01-01)

Acneiform eruption associated with the use of vortioxetine
by: Rukiye Ay, et al.
Published: (2019-04-01)

Comparison of the efficacy of the multimodal serotonergic antidepressants trazodone and vortioxetine in the treatment of patients with endogenous depression: A meta-analysis of double-blind randomized placebo-controlled trials
by: D. S. Danilov
Published: (2017-03-01)

Efficacy of vortioxetine monotherapy compared with combined therapy vortioxetine and olanzapine in the treatment of major depression – first results
by: Oppa M., et al.
Published: (2017-09-01)

Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1
by: Sebastiano Alfio Torrisi, et al.
Published: (2019-06-01)

Anhedonia as a basic syndrome and a target for treatment for depressive disorder
by: G. E. Mazo, et al.
Published: (2019-10-01)

The effect of vortioxetine on penicillin-induced epileptiform activity in rats
by: Muhammed Nur ÖGÜN, et al.

Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial
by: Giovanni Ostuzzi, et al.
Published: (2020-08-01)

Experience with vortioxetine in the treatment of post-stroke depression
by: I. A. Strelnikova, et al.
Published: (2020-02-01)

The efficacy of vortioxetine for the delusional disorder of cenesthopathy
by: Shinji Sato, et al.
Published: (2024-03-01)

Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo
by: Célia Fourrier, et al.
Published: (2018-08-01)

Antidepressants effect on sexual dysfunction in men with PTSD
by: R. Maalej, et al.
Published: (2021-04-01)

DEPRESSION AND COGNITIVE DISTURBANCES: EXPERIENCE OF VORTIOXETINE USE IN NEUROLOGIC PRACTICE
by: Y. E. Azimova
Published: (2017-07-01)

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
by: Eduardo Cumbo, et al.
Published: (2023-01-01)

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea
by: Seok Woo Moon, et al.
Published: (2023-03-01)

Bioequivalence Study of Vortioxetine Hydrobromide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
by: Bai W, et al.
Published: (2023-09-01)

Emotional blunting and cognitive profile in elderly depressed patients in treatment with vortioxetine
by: F. Franza, et al.
Published: (2021-04-01)

The impact of dose on the real-world effectiveness of vortioxetine in outpatients with mdd in greece
by: E. Papalexi, et al.
Published: (2021-04-01)

Serious dermatological adverse effects of vortioxetine: two cases
by: Mesut Cetin, et al.
Published: (2018-07-01)

Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism
by: Daniela Felice, et al.
Published: (2018-03-01)

Efficiency and safety of Vortioxetine in the treatment of depressive disorders in cardiac patients
by: N. V. Filippova, et al.
Published: (2023-06-01)

The effectiveness of vortioxetine in patients with depression in real clinical practice
by: N. N. Petrova
Published: (2022-10-01)

Editorial: Reviews in psychiatry 2022: psychopharmacology
by: Maris Taube, et al.
Published: (2024-02-01)

Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial
by: K.-S. Oh, et al.
Published: (2022-06-01)

Sexual dysfunction induced by antidepressants and antipsychotics
by: O G Lisitsyna, et al.
Published: (2012-10-01)

Effectiveness of vortioxetine in real-world clinical practice: Interim results from the relieve study
by: G. Mattingly, et al.
Published: (2021-04-01)

Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram
by: Shreaya Chakroborty, et al.
Published: (2017-10-01)

Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor
by: Motohiro Okada, et al.
Published: (2021-01-01)

Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
by: A. Galanopoulos, et al.
Published: (2021-04-01)

An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
by: Anish Shah, et al.
Published: (2018-05-01)

Investigations on the Solubility of Vortioxetine Based on X-ray Structural Data and Crystal Contacts
by: Xian-Rui Zhang, et al.
Published: (2019-10-01)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
by: Djamila Bennabi, et al.
Published: (2019-11-01)